Renaissance Capital logo

Cardio Diagnostics (Mana Capital Acquisition) Priced, Nasdaq: CDIO

Blank check company targeting businesses in North America, Europe, and Asia (completed 10/26/2022).

Industry: SPAC

First Day Return: +2.3%

Industry: SPAC

We are a newly formed blank check company. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although we intend to focus our search on target businesses operating in North America, Europe and Asia in the healthcare, technology, green economy and consumer products sectors. To date, our efforts have been limited to organizational activities as well as activities related to this offering. None of our officers, directors, promoters and other affiliates has engaged in any substantive discussions on our behalf with representatives of other companies regarding the possibility of a potential business combination with us. Our management team is led by Jonathan Intrater, Allan Liu and Loren Mortman; each has distinctive and complementary experience and extensive networks in the healthcare, technology, green economy and consumer products sectors as well as various other industries in North America, Europe, and Asia which we believe can provide a suitable selection of potential targets. We intend to focus on targeting middle market entities with a valuation in the $150 million to $500 million range.
more less
IPO Data
IPO File Date 10/19/2021
Offer Price $10.00
Price Range $10.00 - $10.00
Offer Shares (mm) 6.2
Deal Size ($mm) $62
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 11/22/2021
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $62
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Dover, DE, United States
Founded 2021
Employees at IPO 1

Cardio Diagnostics (Mana Capital Acquisition) (CDIO) Performance